Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Clinical Data has received two grants totaling nearly $500,000 under the Qualifying Therapeutic Discovery Project for research and development efforts related to its two late-stage programs Vilazodone and Stedivaze.
Subscribe to our email newsletter
Vilazodone is a novel dual-acting modulator of serotonin neurotransmission in development for the treatment of major depressive disorder with the potential for follow-on indications including generalised anxiety disorder and other related mood disorders.
Stedivaze is a highly selective adenosine 2A receptor agonist in development as a coronary vasodilator for nuclear-SPECT myocardial perfusion imaging.
Clinical Data said that a new drug application for Vilazodone was accepted for review by the US Food and Drug Administration (FDA) on 21 May 2010 with 22 January 2011 currently assigned for decision-making by the FDA under the prescription drug user fee act (PDUFA).
Clinical Data president and CEO Drew Fromkin said that they were pleased that their continued efforts to develop therapies have been recognised with these grants.
"The additional resources will assist us in our ongoing preparations for the launch of Vilazodone upon approval and the continued development of Stedivaze," Fromkin said.